ACOR Acorda Therapeutics Inc

Price (delayed)

$0.5237

Market cap

$6.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$8.19

Enterprise value

$148.85M

Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults ...

Highlights
The company's EPS rose by 46% YoY and by 16% QoQ
ACOR's net income is up by 25% YoY and by 9% QoQ
ACOR's quick ratio is up by 10% YoY but it is down by 9% from the previous quarter
The company's equity fell by 38% YoY and by 16% QoQ
Acorda Therapeutics's gross profit has decreased by 22% YoY

Key stats

What are the main financial stats of ACOR
Market
Shares outstanding
13.29M
Market cap
$6.96M
Enterprise value
$148.85M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.05
Price to sales (P/S)
0.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.21
Earnings
Revenue
$122.74M
EBIT
-$66.96M
EBITDA
-$33M
Free cash flow
-$28.27M
Per share
EPS
-$8.19
Free cash flow per share
-$2.13
Book value per share
$9.63
Revenue per share
$9.26
TBVPS
$7.24
Balance sheet
Total assets
$424.14M
Total liabilities
$296.59M
Debt
$193.35M
Equity
$127.55M
Working capital
$34.46M
Liquidity
Debt to equity
1.52
Current ratio
1.75
Quick ratio
1.38
Net debt/EBITDA
-4.3
Margins
EBITDA margin
-26.9%
Gross margin
71.7%
Net margin
-77.4%
Operating margin
-55%
Efficiency
Return on assets
-20.7%
Return on equity
-60%
Return on invested capital
-35.6%
Return on capital employed
-17.7%
Return on sales
-54.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACOR stock price

How has the Acorda Therapeutics stock price performed over time
Intraday
-7.13%
1 week
-17.53%
1 month
19.57%
1 year
-89.55%
YTD
-78.09%
QTD
-67.47%

Financial performance

How have Acorda Therapeutics's revenue and profit performed over time
Revenue
$122.74M
Gross profit
$87.95M
Operating income
-$67.55M
Net income
-$95.02M
Gross margin
71.7%
Net margin
-77.4%
Acorda Therapeutics's operating income has surged by 52% YoY and by 13% QoQ
ACOR's operating margin is up by 40% year-on-year and by 8% since the previous quarter
ACOR's net income is up by 25% YoY and by 9% QoQ
Acorda Therapeutics's gross profit has decreased by 22% YoY

Growth

What is Acorda Therapeutics's growth rate over time

Valuation

What is Acorda Therapeutics stock price valuation
P/E
N/A
P/B
0.05
P/S
0.06
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.21
The company's EPS rose by 46% YoY and by 16% QoQ
ACOR's P/B is 94% below its 5-year quarterly average of 0.8 and 75% below its last 4 quarters average of 0.2
The company's equity fell by 38% YoY and by 16% QoQ
ACOR's price to sales (P/S) is 93% lower than its 5-year quarterly average of 0.9 and 80% lower than its last 4 quarters average of 0.3
The company's revenue fell by 20% YoY and by 4.9% QoQ

Efficiency

How efficient is Acorda Therapeutics business performance
Acorda Therapeutics's ROE has decreased by 24% YoY and by 2.7% from the previous quarter
The company's return on sales rose by 16% YoY and by 11% QoQ
ACOR's ROIC is up by 15% since the previous quarter but it is down by 9% year-on-year
Acorda Therapeutics's ROA has decreased by 8% YoY

Dividends

What is ACOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACOR.

Financial health

How did Acorda Therapeutics financials performed over time
ACOR's total assets is 43% greater than its total liabilities
ACOR's total assets is down by 27% year-on-year and by 7% since the previous quarter
Acorda Therapeutics's current ratio has increased by 22% YoY but it has decreased by 7% QoQ
Acorda Therapeutics's debt is 52% higher than its equity
The company's equity fell by 38% YoY and by 16% QoQ
Acorda Therapeutics's debt has decreased by 24% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.